Zymeworks ROA 2016-2022 | ZYME

Current and historical return on assets (ROA) values for Zymeworks (ZYME) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Zymeworks ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-06-30 $-0.24B $0.37B -59.20%
2022-03-31 $-0.24B $0.43B -56.34%
2021-12-31 $-0.21B $0.39B -48.11%
2021-09-30 $-0.21B $0.42B -44.17%
2021-06-30 $-0.22B $0.47B -43.24%
2021-03-31 $-0.20B $0.49B -35.34%
2020-12-31 $-0.18B $0.54B -30.76%
2020-09-30 $-0.22B $0.57B -39.38%
2020-06-30 $-0.17B $0.61B -34.19%
2020-03-31 $-0.16B $0.64B -35.60%
2019-12-31 $-0.15B $0.37B -40.82%
2019-09-30 $-0.06B $0.40B -19.74%
2019-06-30 $-0.05B $0.42B -19.43%
2019-03-31 $-0.03B $0.24B -13.53%
2018-12-31 $-0.04B $0.24B -19.40%
2018-09-30 $-0.01B $0.19B -7.99%
2018-06-30 $-0.01B $0.21B -7.18%
2018-03-31 $-0.02B $0.11B -13.02%
2017-12-31 $-0.01B $0.13B -9.37%
2017-09-30 $-0.05B $0.10B -55.53%
2017-06-30 $-0.05B $0.12B -69.20%
2017-03-31 $-0.05B $0.08B -105.75%
2016-12-31 $-0.03B $0.09B -140.43%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.430B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.361B 9.79
GSK (GSK) United Kingdom $73.273B 8.80
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.336B 18.98
Biohaven Pharmaceutical Holding (BHVN) United States $10.564B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.449B 0.00
Arcus Biosciences (RCUS) United States $1.963B 38.31
Myovant Sciences (MYOV) United Kingdom $1.774B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.82
Enzo Biochem (ENZ) United States $0.130B 0.00
Gelesis Holdings (GLS) United States $0.118B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00